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it is one of the most common chronic rheumatic inﬂam-
matory diseases, approximately as common as systemic
lupus erythematosus.1 It is estimated that almost 400,000
Brazilian people suffers from the disease, most of those
did not yet get the diagnosis.2 In the last decade the
number of articles about Sjögren’s syndrome was 5 times
and 10 times less than systemic lupus erythematosus
and rheumatoid arthritis, respectively. Also, in the last
decade, biological therapeutic has revolutionized the treat-
ment of rheumatic disease. Now the time has come for
ﬁnding and testing new targets for treatment of Sjögren’s
syndrome.
There is a global effort to organize large cohorts and reg-
istries, to validate new classiﬁcation criteria and tools to
evaluate disease activity and symptoms, to develop new tar-
gets and to test new treatments for Sjögren’s syndrome.
Recently, new ﬁndings in the pathogenesis, diagnosis and
treatment were discussed among 260 participants of the
13th International Symposium on Sjögren’s syndrome (ISSS),
in Bergen, Norway.1 There, the proposed new ACR-EULAR
classiﬁcation criteria were presented. In spite of not yet
being included ultrasound of salivary glands, the new con-
sensus considers all systemic manifestation included in the
EULAR-Sjögren’s syndrome disease activity index (ESSDAI)
when screening Sjögren’s syndrome. The deﬁnition of disease
activity states and clinically meaningful improvement in pri-
mary Sjögren’s syndrome with ESSDAI and patient-reported
indexes (ESSPRI) were essential to design future studies of
treatment.3,4 Biologic agents targeting B cells (such as rit-
uximab and belimumab) and T cell stimulation inhibition
have shown promising results. Modulation or inhibition of
other targets such as IFN, IL-6 and Toll-like receptor are also
currently being investigated. More  than new targets, in the
future, personalized and cell-based treatment can bring better
results.The current evidence for treating and the urgent need to
standardize the treatment for this disease motivate medi-
cal and patient organizations to create guidelines for treating
Sjögren’s syndrome. At the 13th ISSS, Recommendations from
Brazilian Society of Rheumatology and from Sjögren’s Syn-
drome Foundation (SSF) were presented. Since last year the
EULAR-Task Force is preparing a full guideline.1
The current issue of the Brazilian Journal of Rheumato-
logy brings two articles about Sjögren’s syndrome. One is the
evaluation of psychometric properties of ESSPRI in a Brazilian
population. Currently there are four validated tools useful for
studying Sjógren’s syndrome in Brazil (ESSDAI, ESSPRI, PRO-
FAD and FACIT).5,6
The second article is the Recommendations of Brazil-
ian Society for treatment of Sjögren’s syndrome based on a
systematic review, including 127 articles. The treatment of
glandular involvement was based on a high level of evidence,
but most recommendations for systemic manifestations were
based on case reports. Especially when good evidence is not
available, the recommendations elaborated by a multidis-
ciplinary panel of specialists is an important reference for
treating severe manifestations.
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